http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
-
Aclaris Therapeutics (ACRS) Reports Publication of Abstract of Phase 1 Clinical Trial Results for ATI-450
-
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
-
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
-
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
-
Aclaris Therapeutics Secures $11 Million Term Loan Facility
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
-
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
-
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
-
Aclaris Therapeutics (ACRS) Reports Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450
-
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
-
Aclaris Therapeutics (ACRS) Names Vincent Milano to Board
-
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
-
Aclaris Therapeutics to Present at Upcoming Investor Conferences
-
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
-
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
-
Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1
-
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
-
Aclaris Therapeutics (ACRS) Announces Divestiture of RHOFADE
-
Aclaris Therapeutics Announces Divestiture of RHOFADE®
-
Aclaris Therapeutics (ACRS) Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing ANDA for Generic Version of RHOFADE cream, 1%
-
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
-
Aclaris Therapeutics to Hold R&D Day
-
Aclaris Therapeutics (ACRS) Reports Positive Results from Phase 3 Clinical Trial, THWART-2 (WART-302), of A-101 45% Topical Solution
-
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
-
Aclaris Therapeutics (ACRS) announces new strategic direction, will refocus on its immuno-inflammatory development programs
-
Aclaris Therapeutics Announces New Strategic Direction
-
Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
-
Aclaris Therapeutics (ACRS) Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
-
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
-
Aclaris Therapeutics (ACRS) Reports Issuance of Additional Orange Book Listable Patent Covering RHOFADE (Oxymetazoline Hydrochloride) Cream, 1%
-
Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%
-
Aclaris Therapeutics (ACRS) Names Maxine Gowen to Board
-
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors
-
Aclaris Therapeutics (ACRS) Reports Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-
Aclaris Therapeutics (ACRS) Highlights Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical
-
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
-
Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
-
Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
-
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
-
Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
-
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
-
Aclaris Therapeutics (ACRS) Granted Patent Covering use of Ruxolitinib and Deuterated Forms to Treat Alopecia Areata
-
Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata
-
Aclaris Therapeutics to Attend Upcoming Investor Conference
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
-
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
